Date: 2016-03-15
Type of information: Clinical research agreement
Compound: TB-403
Company: Oncurious (Belgium) BioInvent (Sweden) Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) (USA-MI)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: monoclonal antibody. TB-403 is a humanized monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed by Prof. Peter Carmeliet at the University of Leuven, Belgium.
Disease: neuroblastoma, medulloblastoma and other pediatric cancers
Details: * On March 15, 2016, Oncurious announced that it has signed a partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), a collaboration of 25 US academic medical centers, teaching hospitals and other entities, with the purpose of facilitating and conducting collaborative research activities and investigations of new treatments for neuroblastoma, medulloblastoma and other pediatric cancers. The partnership is a last step in the preparative work by Oncurious and BioInvent International AB before initiating a phase 1-2a program with TB-403 for the treatment of medulloblastoma, neuroblastoma and Ewings sarcoma, all rare, life-threatening pediatric cancers.
BioInvent International is the clinical development partner for the planned TB-403 clinical trial. Final preparations to enable opening the study for enrollment are ongoing.
Financial terms:
Latest news:
